March 20th 2024
Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cabozantinib Combo Does Not Improve Survival in Pretreated, Advanced RCC
June 6th 2023Data from the phase 3 CONTACT-03 trial highlight the necessity of randomized, prospective assessment of re-challenge with checkpoint inhibitors in renal cell carcinoma, according to an expert from Dana-Farber Cancer Institute.
Drug-Free Management Tools Provide Alternatives to Opioids in Kidney Cancer
April 22nd 2023An expert from University Hospitals touches on pain management guidelines that highlight moderate evidence in support of acupuncture, reflexology, and acupressure and massage as tools to manage general pain in patients with cancer.
Value of Collaboration in Managing Patients With Metastatic RCC
Closing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Expert Discusses ‘Impactful’ Guidelines for Integrative Kidney Cancer Care
April 17th 2023An expert from University Hospitals highlights different guidelines penned by oncology organizations informing the integrative management of symptoms including anxiety and depression in patients with kidney cancer.
Novel Therapy in Metastatic RCC: An Evolving Treatment Landscape
Expert panelists share their perspective on novel and combination strategies being investigated in the setting of metastatic renal cell carcinoma.
Clinical Scenario 2: Favorable-Risk Metastatic Renal Cell Carcinoma
Switching focus to a second clinical scenario, key opinion leaders on metastatic renal cell carcinoma discuss the treatment landscape for favorable-risk disease.
Current Prognoses With Metastatic Renal Cell Carcinoma
Before closing out their review of the first clinical scenario, panelists consider the general state of prognoses within metastatic renal cell carcinoma.
Dose Adjusting Therapy for Patients With Metastatic Renal Cell Carcinoma
A brief review of dose hold or adjustment strategies in the setting of metastatic renal cell carcinoma and when it is appropriate to consider these options.